Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Difloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TOP2A | P11388 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.50 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9748366 | 0.88 | LMNA (0.66) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL9749223 | 0.88 | LMNA (0.66) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| Difloxacin SCHEMBL8913761 | 0.86 | ALDH1A1 (0.75) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| Danofloxacin SCHEMBL16518619 | 0.85 | KDM4E (0.62) | LMNAALDH1A1KDM4EHPGDHSD17B10 | |
| Danofloxacin SCHEMBL149627 | 0.85 | KDM4E (0.62) | LMNAALDH1A1KDM4EHPGDHSD17B10 | |
| Danofloxacin SCHEMBL29658817 | 0.85 | KDM4E (0.62) | LMNAALDH1A1KDM4EHPGDHSD17B10 | |
| Danofloxacin SCHEMBL10073753 | 0.85 | KDM4E (0.62) | LMNAALDH1A1KDM4EHPGDHSD17B10 | |
| Danofloxacin SCHEMBL9669908 | 0.85 | KDM4E (0.62) | LMNAALDH1A1KDM4EHPGDHSD17B10 | |
| Danofloxacin SCHEMBL28372629 | 0.84 | KDM4E (0.61) | LMNAALDH1A1KDM4EHPGDHSD17B10 | |
| Difloxacin SCHEMBL148765 | 0.84 | LMNA (1.00) | LMNAMEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228577-A1 | SUBSTITUTED CYCLODEXTRIN-METAL COMPLEXES AND USES THEREOF | BIOCYDEX (FR) | 2021-07-29 | — | — | US | disclosed |
| EP-3790905-A1 | SUBSTITUTED CYCLODEXTRIN-METAL COMPLEXES AND USES THEREOF | Biocydex (FR) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019215285-A1 | SUBSTITUTED CYCLODEXTRIN-METAL COMPLEXES AND USES THEREOF | BIOCYDEX (FR) | 2019-11-14 | — | — | WO | disclosed |
| EP-3567059-A1 | SUBSTITUTED CYCLODEXTRIN-METAL COMPLEXES AND USES THEREOF | Biocydex (FR) | 2019-11-13 | — | — | EP | disclosed |
| EP-0977725-A1 | NEW FATTY ACID DERIVATIVES | NORSK HYDRO ASA (NO) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998032718-A1 | NEW FATTY ACID DERIVATIVES | NORSK HYDRO ASA (NO) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228577-A1 | SUBSTITUTED CYCLODEXTRIN-METAL COMPLEXES AND USES THEREOF | HBB, TBCD, TBCB | LMNA 4830/4885MEN1 3383/4885KMT2A 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.